Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Braz J Microbiol
2012 Oct 01;434:1309-14. doi: 10.1590/S1517-838220120004000010.
Show Gene links
Show Anatomy links
Mutations in the quinolone resistance-determining regions of gyrA and parC in Enterobacteriaceae isolates from Brazil.
Minarini LA
,
Darini AL
.
???displayArticle.abstract???
Mutations in the quinolone resistance-determining regions (QRDR) in chromosomal gyrA and parC genes and fluoroquinolone susceptibility profiles were investigated in quinolone-resistant Enterobacteriaceae isolated from community and hospitalized patients in the Brazilian Southeast region. A total of 112 nalidixic acid-resistant enterobacterial isolates collected from 2000 to 2005 were investigated for mutations in the topoisomerases genes gyrA and parC by amplifying and sequencing the QRDR regions. Susceptibility to fluoroquinolones was tested by the agar dilution method. Amongst the 112 enterobacterial isolates, 81 (72.3%) were resistant to ciprofloxacin and 5 (4.5%) showed reduced susceptibility. Twenty-six (23.2%) were susceptible to ciprofloxacin. Several alterations were detected in gyrA and parC genes. Escherichia coli isolates (47.7%) showed double mutations in the gyrA gene and a single one in the parC gene. Two unusual aminoacid substitutions are reported, an Asp87-Asn in a Citrobacter freundii isolate with reduced susceptibility to fluoroquinolones and a Glu84-Ala in one E. coli isolate. Only a parC gene mutation was found in fluoroquinolone-susceptible Enterobacter aerogenes. None of the isolates susceptible to ciprofloxacin presented mutations in topoisomerase genes. This comprehensive analysis of QRDRs in gyrA and parC genes, covering commonly isolated Enterobacteriaceae in Brazil is the largest reported up to now.
Biedenbach,
Analysis of Salmonella spp. with resistance to extended-spectrum cephalosporins and fluoroquinolones isolated in North America and Latin America: report from the SENTRY Antimicrobial Surveillance Program (1997-2004).
2006, Pubmed
Biedenbach,
Analysis of Salmonella spp. with resistance to extended-spectrum cephalosporins and fluoroquinolones isolated in North America and Latin America: report from the SENTRY Antimicrobial Surveillance Program (1997-2004).
2006,
Pubmed
Chenia,
Analysis of the mechanisms of fluoroquinolone resistance in urinary tract pathogens.
2006,
Pubmed
Deguchi,
Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter cloacae.
1997,
Pubmed
Gales,
Occurrence of single-point gyrA mutations among ciprofloxacin-susceptible Escherichia coli isolates causing urinary tract infections in Latin America.
2000,
Pubmed
Hansen,
Substrate specificity of the OqxAB multidrug resistance pump in Escherichia coli and selected enteric bacteria.
2007,
Pubmed
Hooper,
Fluoroquinolone resistance among Gram-positive cocci.
2002,
Pubmed
Hurst,
Levofloxacin: an updated review of its use in the treatment of bacterial infections.
2002,
Pubmed
Jacoby,
Impact of hospital-wide infection rate, invasive procedures use and antimicrobial consumption on bacterial resistance inside an intensive care unit.
2010,
Pubmed
Mammeri,
Emergence of plasmid-mediated quinolone resistance in Escherichia coli in Europe.
2005,
Pubmed
MartÃnez-MartÃnez,
Quinolone resistance from a transferable plasmid.
1998,
Pubmed
Minarini,
First report of plasmid-mediated resistance to quinolones and cefotaxime in an Enterobacter cloacae strain isolated from an outpatient in Brazil.
2007,
Pubmed
Minarini,
Prevalence of community-occurring extended spectrum beta-lactamase-producing Enterobacteriaceae in Brazil.
2007,
Pubmed
Moon,
Emergence of a new mutation and its accumulation in the topoisomerase IV gene confers high levels of resistance to fluoroquinolones in Escherichia coli isolates.
2010,
Pubmed
Naheed,
Fluoroquinolone-resistant Shigella dysenteriae type 1 in northeastern Bangladesh.
2004,
Pubmed
Nordmann,
Emergence of plasmid-mediated resistance to quinolones in Enterobacteriaceae.
2005,
Pubmed
Ogbolu,
High levels of multidrug resistance in clinical isolates of Gram-negative pathogens from Nigeria.
2011,
Pubmed
Pereira,
Evaluation of the susceptibility profiles, genetic similarity and presence of qnr gene in Escherichia coli resistant to ciprofloxacin isolated in Brazilian hospitals.
2007,
Pubmed
Poole,
Efflux-mediated antimicrobial resistance.
2005,
Pubmed
Robicsek,
Broader distribution of plasmid-mediated quinolone resistance in the United States.
2005,
Pubmed
Ruiz,
Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection.
2003,
Pubmed
Tumbarello,
Identifying patients harboring extended-spectrum-beta-lactamase-producing Enterobacteriaceae on hospital admission: derivation and validation of a scoring system.
2011,
Pubmed
Vernaz,
Modelling the impact of antibiotic use on antibiotic-resistant Escherichia coli using population-based data from a large hospital and its surrounding community.
2011,
Pubmed
Vila,
Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichia coli and MICs.
1994,
Pubmed
Weigel,
gyrA mutations associated with fluoroquinolone resistance in eight species of Enterobacteriaceae.
1998,
Pubmed
Yamane,
New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.
2007,
Pubmed
